{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:12:49Z","timestamp":1791288769548,"version":"4.3.0"},"reference-count":53,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100000295","name":"Epilepsy Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Recent biochemical observations have helped redefine antigenic components within the voltage-gated potassium channel (VGKC) complex. The related autoantibodies may be now divided into likely pathogenic entities, which target the extracellular domains of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2), and species that target intracellular neuronal components and are likely non-pathogenic. This distinction has enhanced clinical practice as direct determination of LGI1 and CASPR2 antibodies offers optimal sensitivity and specificity. In this review, we describe and compare the clinical features associated with pathogenic LGI1 and CASPR2 antibodies, illustrate emerging laboratory techniques for antibody determination and describe the immunological mechanisms that may mediate antibody-induced pathology. We highlight marked clinical overlaps between patients with either LGI1 or CASPR2 antibodies that include frequent focal seizures, prominent amnesia, dysautonomia, neuromyotonia and neuropathic pain. Although occurring at differing rates, these commonalities are striking and only faciobrachial dystonic seizures reliably differentiate these two conditions. Furthermore, the coexistence of both LGI1 and CASPR2 antibodies in an individual occurs surprisingly frequently. Patients with either antibody respond well to immunotherapies, although systematic studies are required to determine the magnitude of the effect beyond placebo. Finally, data have suggested that CASPR2 and LGI1 modulation via genetic or autoimmune mechanisms may share common intermediate molecules. Taken together, the biochemical distinction of antigenic targets has led to important clinical advances for patient care. However, the striking syndrome similarities, coexistence of two otherwise rare antibodies and molecular insights suggest the VGKC complex may yet be a common functional effector of antibody action. Hence, we argue for a molecular evolution alongside a clinical and phenotypic re-evaluation.<\/jats:p>","DOI":"10.1136\/jnnp-2017-315720","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T12:12:34Z","timestamp":1508760754000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":213,"title":["LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes"],"prefix":"10.1136","volume":"89","author":[{"given":"Sophie N M","family":"Binks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh R","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,10,21]]},"reference":[{"key":"2020050722294620000_89.5.526.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24200"},{"key":"2020050722294620000_89.5.526.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318224afde"},{"key":"2020050722294620000_89.5.526.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7600-8"},{"key":"2020050722294620000_89.5.526.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq213"},{"key":"2020050722294620000_89.5.526.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314758"},{"key":"2020050722294620000_89.5.526.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70137-X"},{"key":"2020050722294620000_89.5.526.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380505"},{"key":"2020050722294620000_89.5.526.8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722294620000_89.5.526.9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt212"},{"key":"2020050722294620000_89.5.526.10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2020050722294620000_89.5.526.11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1-associated cognitive impairment: presentation and long-term outcome","volume":"87","author":"Ari\u00f1o","year":"2016","journal-title":"Neurology"},{"key":"2020050722294620000_89.5.526.12","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3633"},{"key":"2020050722294620000_89.5.526.13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23577"},{"key":"2020050722294620000_89.5.526.14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaneurol.2013.592","article-title":"Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping","volume":"70","author":"Klein","year":"2013","journal-title":"JAMA Neurol"},{"key":"2020050722294620000_89.5.526.15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22307"},{"key":"2020050722294620000_89.5.526.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001326"},{"key":"2020050722294620000_89.5.526.17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh077"},{"key":"2020050722294620000_89.5.526.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2020050722294620000_89.5.526.19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ana.22674","article-title":"Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol","volume":"71","author":"Meeusen","year":"2012","journal-title":"Ann Neurol"},{"key":"2020050722294620000_89.5.526.20","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.2985"},{"key":"2020050722294620000_89.5.526.21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","article-title":"Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures","volume":"73","author":"Joubert","year":"2016","journal-title":"JAMA Neurol"},{"key":"2020050722294620000_89.5.526.22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","article-title":"Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies","volume":"74","author":"Finke","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020050722294620000_89.5.526.23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww012"},{"key":"2020050722294620000_89.5.526.24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.seizure.2017.05.017","article-title":"LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures","volume":"50","author":"Aurangzeb","year":"2017","journal-title":"Seizure"},{"key":"2020050722294620000_89.5.526.25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"key":"2020050722294620000_89.5.526.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306724"},{"key":"2020050722294620000_89.5.526.27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx070"},{"key":"2020050722294620000_89.5.526.28","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3506-13.2013"},{"key":"2020050722294620000_89.5.526.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301506"},{"key":"2020050722294620000_89.5.526.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182886991"},{"key":"2020050722294620000_89.5.526.31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1212\/WNL.0000000000002547","article-title":"Orthostatic myoclonus associated with Caspr2 antibodies","volume":"86","author":"G\u00f6vert","year":"2016","journal-title":"Neurology"},{"key":"2020050722294620000_89.5.526.32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.25371","article-title":"Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy","volume":"55","author":"Lahoria","year":"2017","journal-title":"Muscle Nerve"},{"key":"2020050722294620000_89.5.526.33","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jamaneurol.2014.1234","article-title":"Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex\/leucine-rich, glioma inactivated 1 antibody encephalitis","volume":"71","author":"Naasan","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020050722294620000_89.5.526.34","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.130039"},{"key":"2020050722294620000_89.5.526.35","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1212\/NXI.0000000000000161","article-title":"Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures","volume":"2","author":"Flanagan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2020050722294620000_89.5.526.36","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276946.08412.ef"},{"key":"2020050722294620000_89.5.526.37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws082"},{"key":"2020050722294620000_89.5.526.38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ene.13180","article-title":"Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome","volume":"24","author":"Bien","year":"2017","journal-title":"Eur J Neurol"},{"key":"2020050722294620000_89.5.526.39","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1212\/NXI.0000000000000207","article-title":"Immunoadsorption therapy in autoimmune encephalitides","volume":"3","author":"Dogan Onugoren","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2020050722294620000_89.5.526.40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamaneurol.2014.463","article-title":"Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy","volume":"71","author":"Irani","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020050722294620000_89.5.526.41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.24860","article-title":"Anti-LGI1 encephalitis is associated with unique HLA subtypes","volume":"81","author":"Kim","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722294620000_89.5.526.42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.24858","article-title":"Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4","volume":"81","author":"van Sonderen","year":"2017","journal-title":"Ann Neurol"},{"key":"2020050722294620000_89.5.526.43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2020050722294620000_89.5.526.44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914537107"},{"key":"2020050722294620000_89.5.526.45","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20925"},{"key":"2020050722294620000_89.5.526.46","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000264932.44153.3c"},{"key":"2020050722294620000_89.5.526.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618656114"},{"key":"2020050722294620000_89.5.526.48","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4661-09.2010"},{"key":"2020050722294620000_89.5.526.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.040"},{"key":"2020050722294620000_89.5.526.50","doi-asserted-by":"crossref","unstructured":"Coutinho E , Jacobson L , Pedersen MG , et al . CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. J Neuro Neurosurg Psychiatry 2017.","DOI":"10.1136\/jnnp-2016-315251"},{"key":"2020050722294620000_89.5.526.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2007.09.005"},{"key":"2020050722294620000_89.5.526.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052773"},{"key":"2020050722294620000_89.5.526.53","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90073-X"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-315720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:07:44Z","timestamp":1601042864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-315720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,21]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,12]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/jnnp-2017-315720"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-315720","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,21]]}}}